Summary:
Bio-Rad has expanded its portfolio of recombinant monoclonal anti-idiotypic antibodies and SpyCatcher reagents to support enhanced bioanalytical assay development and therapeutic drug monitoring for biologics.
Takeaways:
- Expanded Antibody Coverage: New anti-idiotypic antibodies target key biologics—including pertuzumab, guselkumab, canakinumab, belimumab, and emicizumab—supporting pharmacokinetic and ADA assays.
- Innovative SpyCatcher Tool: The newly added Human IgM-FcSpyCatcher enables rapid antibody format switching and multimeric IgM assembly for advanced assay flexibility.
- Research and Commercial Utility: All new products are approved for in vitro research, with antibodies also cleared for use in commercial testing during drug development and patient monitoring.
Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies specific to pertuzumab (Perjeta), guselkumab (Tremfya), canakinumab (Ilaris), belimumab (Benlysta), and the bispecific drug emicizumab (Hemlibra). The Company has also extended its range of SpyCatcher reagents to include Human IgM-FcSpyCatcher.
Bio-Rad’s comprehensive range of anti-biotherapeutic antibodies enables the development of robust and reliable bioanalytical assays against biologic drugs and is suitable for use in pharmacokinetic (PK) and anti-drug-antibody (ADA) assays for pertuzumab, guselkumab, canakinumab, belimumab, and emicizumab, facilitating therapeutic drug monitoring for innovator and biosimilar products.
SpyCatcher Collection Is Unique Reagent
The new Human IgM-FcSpyCatcher adds to Bio-Rad’s SpyCatcher collection—it is a unique reagent that allows researchers to rapidly switch antibody formats at the protein level, enabling spontaneous formation of pentameric and hexameric IgMs. Compatible with Bio-Rad’s recombinant HuCAL antibodies, the new SpyCatcher reagent has been successfully tested in ELISA, western blotting, and precipitation assays.
“Bio-Rad’s leading portfolio of monoclonal anti-idiotypic antibodies is extensive; with 45 different specificities and more than 250 antibodies, we are providing greater flexibility for the development of highly selective and highly sensitive bioanalytical assays,” says Hilary Mavor, marketing director, Life Science Group, Bio-Rad. “With the addition of the new SpyCatcher protein, we are continuing to deliver new and innovative bioanalysis tools for both our custom and catalog antibody customers, driving advances in antibody drug discovery.”
Anti-Idiotypic Antibodies Approved for Commercial In Vitro Testing
The new antibodies and reagents are approved for in vitro research, with the anti-idiotypic antibodies also approved for commercial in vitro testing services to support preclinical and clinical drug and biosimilar development, and patient monitoring.
Featured Image: Bio-Rad Laboratories has extended its range of recombinant monoclonal anti-idiotypic antibodies. Image: Bio-Rad Laboratories
